Skip to main content
. Author manuscript; available in PMC: 2017 Sep 5.
Published in final edited form as: Cancer Immunol Res. 2014 Aug 7;2(11):1059–1070. doi: 10.1158/2326-6066.CIR-14-0051

Figure 4. Effect of GD2 CAR T-cells on disseminated neuroblastoma.

Figure 4

(A) An initial infusion of RNA GD2 CAR T-cells reduces disease burden, while the subsequent infusions modestly stabilize disease. (B) Lentiviral GD2 CAR T-cells mediate long-term disease control. On day 28 a transient disease recurrence appears, but is eliminated, highlighting the memory response of permanently-modified CAR T-cells.